Drug Database · Clinicians

Doxorubicin

Brands (64) Axibin, Dactorubin, Doxocare…Show all

US brand (reference label): Doxorubicin Hydrochloride; not a Philippine-registered brand.

Antineoplastic (anthracycline and related substance); Antineoplastic (cell-cycle specific Agent/Anthracycline); and others PH FDA category

Rx · Prescription drug77 PH productsPNF-listedVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 1fd148fb-0fbc-4b6f-b790-23546fb46a71, version date May 5, 2026 (Doxorubicin Hydrochloride · Pfizer Laboratories Div Pfizer Inc). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • as a component of multi‑agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer
  • for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft…
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated:

  • as a component of multi‑agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1)
  • for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2) 1.1 Adjuvant Breast Cancer Doxorubicin Hydrochloride Injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer. 1.2 Other Cancers Doxorubicin Hydrochloride Injection is indicated for the treatment of
  • acute lymphoblastic leukemia
  • acute myeloblastic leukemia
  • Hodgkin lymphoma
  • non-Hodgkin lymphoma (NHL)
  • metastatic breast cancer
  • metastatic Wilms' tumor
  • metastatic neuroblastoma
  • metastatic soft tissue sarcoma
  • metastatic bone sarcoma
  • metastatic ovarian carcinoma
  • metastatic transitional cell bladder carcinoma
  • metastatic thyroid carcinoma
  • metastatic gastric carcinoma
  • metastatic bronchogenic carcinoma

Contraindications

4 CONTRAINDICATIONS Doxorubicin Hydrochloride Injection are contraindicated in patients with:

  • Severe myocardial insufficiency [see Warnings and Precautions (5.1)]
  • Recent (occurring within the past 4-6 weeks) myocardial infarction [see Warnings and Precautions (5.1)]
  • Severe persistent drug-induced myelosuppression [see Warnings and Precautions (5.4)]
  • Severe hepatic impairment (defined as Child Pugh Class C or serum bilirubin level greater than 5 mg/dL) [see Warnings and Precautions (5.5)]
  • Severe hypersensitivity reaction to doxorubicin hydrochloride, including anaphylaxis [see Adverse Reactions (6.2)]
  • Severe myocardial insufficiency (4)
  • Recent myocardial infarction (4)
  • Severe persistent drug-induced myelosuppression (4)
  • Severe hepatic impairment (4)
  • Severe hypersensitivity to doxorubicin hydrochloride (4)
US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • • Single agent: 60 to 75 mg/m 2 given intravenously every 21 days (2.2)
  • • In combination: 40 to 75 mg/m 2 given intravenously every 21 to 28 days (2.2)
  • • Discontinue Doxorubicin Hydrochloride Injection in patients who develop signs or symptoms of cardiomyopathy (2.3)
  • • Reduce dose in patients with hepatic impairment (2.4)
2.1 Recommended Dosage for Adjuvant Breast Cancer

2.1 Recommended Dosage for Adjuvant Breast Cancer The recommended dosage of Doxorubicin Hydrochloride Injection is 60 mg/m 2 administered as an intravenous bolus on day 1 of each 21-day treatment cycle, in combination with cyclophosphamide, for a total of four cycles.

2.2 Recommended Dosage for Other Cancers

2.2 Recommended Dosage for Other Cancers

  • The recommended dosage of Doxorubicin Hydrochloride Injection when used as a single agent is 60 mg/m 2 to 75 mg/m 2 intravenously every 21 days.
  • The recommended dosage of Doxorubicin Hydrochloride Injection, when administered in combination with other chemotherapy drugs, is 40 mg/m 2 to 75 mg/m 2 intravenously every 21 to 28 days.
  • Consider use of the lower Doxorubicin Hydrochloride Injection dose in the recommended dosage range or longer intervals between cycles for heavily pretreated patients, elderly patients, or obese patients.
  • Cumulative doses above 550 mg/m 2 are associated with an increased risk of cardiomyopathy [see Warnings and Precautions (5.1)].
2.3 Dosage Modifications for Adverse Reactions Cardiomyopathy

2.3 Dosage Modifications for Adverse Reactions Cardiomyopathy Discontinue Doxorubicin Hydrochloride Injection in patients who develop signs or symptoms of cardiomyopathy [see Warnings and Precautions (5.1)].

2.4 Dosage Modifications for Hepatic Impairment

2.4 Dosage Modifications for Hepatic Impairment Doxorubicin Hydrochloride Injection is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C or serum bilirubin greater than 5 mg/dL) [see Contraindications (4)]. Dosage modifications for Doxorubicin Hydrochloride Injection in patients with elevated serum total bilirubin concentrations [see Warnings and Precautions (5.5), Use in Specific Populations (8.6)] are provided in Table 1.

Table 1. Recommended Dosage Modification for Elevated Serum Total Bilirubin Serum Total Bilirubin Concentration Dosage Modification 1.2–3 mg/dL 50% 3.1–5 mg/dL 75% Greater than 5 mg/dL Do not initiate Doxorubicin Hydrochloride Injection; discontinue Doxorubicin Hydrochloride Injection

2.5 Preparation and Administration

2.5 Preparation and Administration Doxorubicin Hydrochloride Injection is a hazardous drug. Follow applicable special handling and disposal procedures. 1 Preparation Dilution of Doxorubicin Hydrochloride Injection

  • Dilute Doxorubicin Hydrochloride Injection in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP.
  • Protect from light following preparation until completion of infusion.
  • Use within 1 hour. If not used within 1 hour, discard the diluted product. Administration
  • Visually inspect for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard if the solution is discolored, cloudy, or contains particulate matter. Administration by Intravenous Injection
  • Administer diluted Doxorubicin Hydrochloride Injection as an intravenous injection through a central intravenous line or a secure and free-flowing peripheral venous line containing 0.9% Sodium Chloride Injection, USP, 0.45% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP.
  • Administer intravenously over 3 to 10 minutes. Decrease the rate of infusion if erythematous streaking along the vein proximal to the site of infusion or facial flushing occur. Administration by Continuous Intravenous Infusion
  • Administer diluted Doxorubicin Hydrochloride Injection solution only through a central intravenous line. Decrease the rate of infusion if erythematous streaking along the vein proximal to the site of infusion or facial flushing occur.
  • Protect from light from preparation for infusion until completion of infusion. Management of Suspected Extravasation Immediately discontinue Doxorubicin Hydrochloride Injection for burning or stinging sensation or other evidence indicating peri-venous infiltration or extravasation. Manage confirmed or suspected extravasation as follows:
  • Do not remove the needle until attempts are made to aspirate extravasated fluid.
  • Do not flush the line.
  • Avoid applying pressure to the site.
  • Apply ice to the site intermittently for 15 minutes, 4 times a day for 3 days.
  • If the extravasation is in an extremity, elevate the extremity.
  • In adults, consider administration of dexrazoxane [see Warnings and Precautions (5.3)]. Management of Contact with Skin or Eyes Treat accidental contact with the skin or eyes immediately by copious lavage with water, or soap and water, or sodium bicarbonate solution. Do not abrade the skin by using a scrub brush. Seek medical attention. Incompatibility with Other Drugs Do not admix Doxorubicin Hydrochloride Injection with other drugs. If Doxorubicin Hydrochloride Injection is mixed with heparin or fluorouracil, a precipitate may form. Avoid contact with alkaline solutions which can lead to hydrolysis of doxorubicin hydrochloride.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.6 Hepatic Impairment The clearance of doxorubicin was reduced in patients with elevated serum total bilirubin levels. Doxorubicin Hydrochloride Injection is contraindicated in patients with severe hepatic impairment (defined as Child Pugh Class C or serum bilirubin levels greater than 5 mg/dL) [see Contraindications (4)]. Reduce the dose of Doxorubicin Hydrochloride Injection in patients with serum total bilirubin levels greater than 1.2 mg/dL [See Dosage and Administration (2.4), Warnings and Precautions (5.5)].

2.4 Dosage Modifications for Hepatic Impairment Doxorubicin Hydrochloride Injection is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C or serum bilirubin greater than 5 mg/dL) [see Contraindications (4)]. Dosage modifications for Doxorubicin Hydrochloride Injection in patients with elevated serum total bilirubin concentrations [see Warnings and Precautions (5.5), Use in Specific Populations (8.6)] are provided in Table 1.

Table 1. Recommended Dosage Modification for Elevated Serum Total Bilirubin Serum Total Bilirubin Concentration Dosage Modification 1.2–3 mg/dL 50% 3.1–5 mg/dL 75% Greater than 5 mg/dL Do not initiate Doxorubicin Hydrochloride Injection; discontinue Doxorubicin Hydrochloride Injection

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Based on postmarketing reports, pediatric patients treated with doxorubicin hydrochloride are at risk for developing late cardiovascular dysfunction. Risk factors include young age at treatment (especially < 5 years), high cumulative doses and receipt of combined modality therapy. Long-term periodic cardiovascular monitoring is recommended for all pediatric patients who have received doxorubicin hydrochloride.

Doxorubicin hydrochloride, as a component of intensive chemotherapy regimens administered to pediatric patients, may contribute to prepubertal growth failure and may also contribute to gonadal impairment, which is usually temporary. There are no recommended dose adjustments based on age. Doxorubicin clearance was increased in patients aged 2 years to 20 years as compared to adults, while doxorubicin clearance was similar in infants less than 2 years as compared to adults [see Clinical Pharmacology (12.3)].

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Clinical experience in patients who were 65 years of age and older who received doxorubicin hydrochloride-based chemotherapy regimens for metastatic breast cancer showed no overall differences in safety and effectiveness compared with younger patients.

Administration

2.5 Preparation and Administration Doxorubicin Hydrochloride Injection is a hazardous drug. Follow applicable special handling and disposal procedures. 1 Preparation Dilution of Doxorubicin Hydrochloride Injection • Dilute Doxorubicin Hydrochloride Injection in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. • Protect from light following preparation until completion of infusion. • Use within 1 hour. If not used within 1 hour, discard the diluted product. Administration • Visually inspect for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard if the solution is discolored, cloudy, or contains particulate matter. Administration by Intravenous Injection • Administer diluted Doxorubicin Hydrochloride Injection as an intravenous injection through a central intravenous line or a secure and free-flowing peripheral venous line containing 0.9% Sodium Chloride Injection, USP, 0.45% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP. • Administer intravenously over 3 to 10 minutes. Decrease the rate of infusion if erythematous streaking along the vein proximal to the site of infusion or facial flushing occur. Administration by Continuous Intravenous Infusion • Administer diluted Doxorubicin Hydrochloride Injection solution only through a central intravenous line. Decrease the rate of infusion if erythematous streaking along the vein proximal to the site of infusion or facial flushing occur. • Protect from light from preparation for infusion until completion of infusion. Management of Suspected Extravasation Immediately discontinue Doxorubicin Hydrochloride Injection for burning or stinging sensation or other evidence indicating peri-venous infiltration or extravasation. Manage confirmed or suspected extravasation as follows: • Do not remove the needle until attempts are made to aspirate extravasated fluid. • Do not flush the line. • Avoid applying pressure to the site. • Apply ice to the site intermittently for 15 minutes, 4 times a day for 3 days. • If the extravasation is in an extremity, elevate the extremity. • In adults, consider administration of dexrazoxane [see Warnings and Precautions (5.3) ] . Management of Contact with Skin or Eyes Treat accidental contact with the skin or eyes immediately by copious lavage with water, or soap and water, or sodium bicarbonate solution. Do not abrade the skin by using a scrub brush. Seek medical attention. Incompatibility with Other Drugs Do not admix Doxorubicin Hydrochloride Injection with other drugs. If Doxorubicin Hydrochloride Injection is mixed with heparin or fluorouracil, a precipitate may form. Avoid contact with alkaline solutions which can lead to hydrolysis of doxorubicin hydrochloride.

US FDA label

Dosage forms

Philippines

  • Lyophilized powder for injection: 10 mg, 50 mg
  • Solution for injection: 2 mg/mL
  • Lyophilized powder for iv injection/infusion: 10 mg, 50 mg
  • ) solution for injection: 2 mg/mL (10 mg/5 mL, 2 mg/mL (50 mg/25 mL, 10 mg/5 mL (2 mg/mL
  • ) solution for liposomal injection: 2 mg/mL (20 mg/10 mL, 2 mg/mL (50 mg/25 mL
  • Lyophilized powder for injection for i.v. infusion: 10 mg, 50 mg
  • Lyophilized powder for intravenous injection: 10 mg, 50 mg
  • ) concentrate solution for iv infusion: 2 mg/mL (50 mg/25 mL
  • ) pegylated liposomal concentrate for solution for injection: 2 mg/mL (20 mg/10 mL
  • ) pegylated liposomal concentrate solution for i.v. infusion: 2 mg/mL (20 mg/10 mL

and 10 more forms; see the products table.

Registered products in the Philippines

77 products registered with the Food and Drug Administration (FDA) Philippines list Doxorubicin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products77
Philippine FDA-registered products for Doxorubicin
Package insert
AD MycinDoxorubicin Hydrochloride
2 mg/mL Solution for Injection (IV)USP Type I Clear and Colorless glass vial x 5 mL and 25 mL (Box of 10's)
RxVAT-exempt
Boryung Pharmaceutical Co., LtdRepublic of Korea
Endure Medical, Inc.
DR-XY32895
Feb 1, 2029
Adriblastina RDDoxorubicin Hydrochloride
50 mg Lyophilized Powder for Injection (IV)25 mL-Capacity Type I Colorless Glass Vial with chlorobutyl Rubber stopper and Aluminum Seal with a Polypropylene Flip-off Top (Box of 1's)
RxVAT-exempt
Corden Pharma Latina S.P.A.italy
Importer: Pfizer, Inc.
DRP-3413
Feb 9, 2028
AdrimDoxorubicin hydrochloride
2 mg/mL Solution for injection (I.V. Infusion)USP Type I Clear Glass Vial x 5 mL (Box of 1's); USP Type I Clear Glass Vial x 30 mL (25 mL net content) (Box of 1's)
RxVAT-exempt
Fresenius Kabi Oncology LimitedIndia
Fresenius Kabi Philippines Inc.
DR-XY42324
Jul 31, 2028
AdrycinDoxorubicin hydrochloride
2 mg/mL (20 mg/10 mL) Pegylated Liposomal Concentrate Suspension for Injection (I.V. Infusion)USP Type I glass vial with gray color rubber stopper and white color flip off seal x 10 mL (Box of 1's)
RxVAT-exempt
Hetero Labs Limited (Unit VI)India
Camber Pharmaceuticals, Inc.
DRP-15770
Sep 12, 2029
Anthra-50Doxorubicin Hydrochloride
50 mg Lyophilized Powder for Injection (I.V.)30 mL-Capacity USP Type I Clear Glass Vial with Bromobutyl Rubber Stopper and Magenta colored Aluminum Flip-Off Seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
—
DRP-13423
Feb 15, 2028
AxbinDoxorubicin hydrochloride
50 mg Lyophilized Powder for Injection (I.V.)Type I colorless glass vial with bromobutyl rubber stopper and sealed with red aluminum cap x 40 mL (Box of 1’s)
RxVAT-exempt
Korea United Pharm. Inc.Korea
Qualimed Pharma Inc.
DR-XY49223
Sep 24, 2029
AxibinDoxorubicin hydrochloride
10mg Lyophilized Powder for Injection (IV)USP Type I Clear, Colorless Glass Vial (Box of 1's)
RxVAT-exempt
Korea United Pharm. Inc.Korea
Qualimed Pharma Inc.
DR-XY49520
Sep 16, 2030
AxibinDoxorubicin hydrochloride
2 mg/mL Solution for Injection (I.V.)USP Type I Clear, Colorless Glass Vial x 5 mL and 25 mL (Box of 1's)
RxVAT-exempt
Korea United Pharm. Inc.Republic of Korea
Qualimed Pharma Inc.
DR-XY31187
Oct 18, 2031
BDLYPODoxorubicin Hydrochloride
2 mg/mL (20 mg/mL) Pegylated Liposomal Concentrated Solution for I.V. InfusionUSP Type I Flint Tubular Glass Vial x 10 mL (Net Content) (Box of 1’s)
RxVAT-exempt
Khandelwal Laboratories Pvt. Ltd.India
Pharma 518, Inc.Importer: Ambica International CorporationTrader: BDR Pharmaceuticals Int’l Pvt. Ltd.
DRP-7095
Jan 16, 2032
BicindoxilDoxorubicin hydrochloride
2 mg/mL Solution for Injection (I.V.)5 mL and 30 mL Type I Amber Glass Vial with Net Content of 5 mL and 25 mL, respectively (Box of 1’s)
RxVAT-exempt
Getwell PharmaceuticalsIndia
Globo Asiatico Enterprises, Inc.Importer: Ambica International Corporation
DRP-4794-05
Oct 7, 2028
ChemodoxDoxorubicin Hydrochloride
2 mg/mL Pegylated Liposomal Concentrate Solution for IV InfusionUSP Type I Tubular glass vial with 20 mm bromobutyl rubber stopper and 20 mm light blue flip off seal x 10 mL (Box of 1's)
RxVAT-exempt
Sun Pharmaceutical Industries Ltd.India
Sun Pharma Philippines, Inc.
DRP-8740
Feb 5, 2028
D-Xobin 10Doxorubicin hydrochloride
2 mg/mL (10 mg/5 mL) Solution for Injection (I.V.)USP Type I amber-colored tubular glass vial sealed with 20 mm grey bromo butyl rubber plug, aluminum seal, and 20 mm red flip off cap x 5 mL (Box of 1's)
RxVAT-exempt
Venus Remedies, LimitedIndia
Delex Pharma International, Inc.Importer: Aglobal Care, Inc.
DRP-9148-01
Oct 10, 2031
D-Xobin 50Doxorubicin hydrochloride
2 mg/mL (50 mg/25 mL) Solution for Injection (I.V.)USP Type I amber-colored tubular glass vial sealed with 20 mm grey bromo butyl rubber plug, aluminum seal, and 20 mm red flip off cap x 25 mL (Box of 1's)
RxVAT-exempt
Venus Remedies LimitedIndia
Delex Pharma International, Inc.Importer: Aglobal Care, Inc.
DRP-9229-01
Nov 19, 2031
DactorubinDoxorubicin Hydrochloride
10 mg Lyophilized Powder for Injection (I.V.)Flint Tubular Type I Glass Vial with 20 mm Slotted GBBR Stopper and sealed with White Flip-Off Aluminum Seal x 5 mL (Box of 1's)
RxVAT-exempt
Khandelwal Laboratories Pvt. Ltd.India
Medethix, Inc.
DRP-10196
Oct 1, 2031
DactorubinDoxorubicin (as Hydrochloride)
50 mg Lyophilized Powder for Injection (IV)Flint Tubular Type I Glass Vial x 25 mL with 20 mm Slotted GBBR Stopper and Sealed with White Flip-Off Aluminum Seal (Box of 1's)
RxVAT-exempt
Khandelwal Laboratories Pvt. Ltd.India
Medethix, Inc.
DRP-10197
Oct 1, 2031
Dobucin-50Doxorubicin hydrochloride
50 mg Lyophilized Powder for Injection (IV)30 mL capacity USP Type I clear and colorless glass vial sealed with bromobutyl rubber stopper and red flip-off seal (Box of 1's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-7540
Dec 7, 2027
DorugemDoxorubicin hydrochloride
2 mg/mL Solution for Injection (I.V.)30 mL Type I Amber Glass Vial with Net Content of 25 mL (Box of 1’s)
RxVAT-exempt
Getwell PharmaceuticalsIndia
Diafarm Inc.Importer: Ambica International Corporation
DRP-4794-02
Oct 7, 2028
DoxGet-50Doxorubicin Hydrochloride
50 mg Lyophilized Powder For Injection (IV)30 mL -capacity USP Type I Clear Glass Vial with Grey Bromobutyl rubber stooper and Aluminum flip-off seal (Box of 1's)
RxVAT-exempt
Beta Drugs LimitedIndia
2MG Incorporated
DRP-18282
Jun 4, 2031
Doxilyd 10Doxorubicin Hydrochloride
10 mg Lyophilized Powder for Injection (IV)USP Type I Glass Vial (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
I.E. Medica, Inc.
DRP-2299
Jul 2, 2028
Doxilyd 50Doxorubicin Hydrochloride
50 mg Lyophilized Powder for Injection (IV)USP Type I Glass Vial with Rubber Stopper and Red Flip-off Seal Box of 1's
RxVAT-exempt
Celon Laboratories Private LimitedIndia
I.E. Medica, Inc.
DRP-2300
Jul 2, 2028
DoxobicinDoxorubicin hydrochloride
2 mg/mL Solution for Injection (I.V.)5 mL and 30 mL Type I Amber Glass Vial with Net Content of 5 mL and 25 mL, respectively Box of 1’s
RxVAT-exempt
Getwell PharmaceuticalsIndia
Detoxicare Philippines, Inc.Importer: Ambica International Corporation
DRP-4794-06
Oct 7, 2028
DoxocareDoxorubicin Hydrochloride
10 mg Lyophilized Powder for Injection (IV)USP Type I Tubular Flint Vial with red Flip-off cap (Box of 1's)
RxVAT-exempt
Naprod Life Sciences Pvt. Ltd.India
Multicare Pharmaceuticals Phils. IncImporter: Multicare Pharmaceuticals Phils. Inc.
DRP-2741
Mar 5, 2031
DoxocareDoxorubicin Hydrochloride
50 mg Lyophilized Powder for Injection (IV)USP Type I Tubular Flint vial with red Flip-off cap (Box of 1's)
RxVAT-exempt
Naprod Life Sciences Pvt. Ltd.India
Multicare Pharmaceuticals Phils. Inc.
DRP-2718
Mar 4, 2031
Doxoccord 20 LPDoxorubicin Hydrochloride
2 mg/mL (20 mg/10 mL) Pegylated Liposomal Concentrate for Solution for Injection (IV Infusion)Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper with Blue Flip-Off Seal Cap x 10 mL (Box of 1's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Importer: Accord Healthcare Limited-Philippine Branch Office
DRP-10846
Dec 6, 2026
Doxoccord 50 LPDoxorubicin Hydrochloride
2 mg/mL (50 mg/25 mL) Pegylated Liposomal Concentrate Solution for Injection (IV Infusion)Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper with Red Flip-Off Seal Cap x 30 mL (Net content: 25 mL) (Box of 1's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Accord Healthcare Limited - Philippine BranchImporter: Accord Healthcare Limited-Philippine Branch Office
DRP-10845
Dec 6, 2026
DoxoHealth 10Doxorubicin Hydrochloride
10 mg Lyophilized Powder for IV Injection/InfusionUSP Type I Clear and Colorless Glass Vial with pink cover (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp.
DRP-8962-02
Aug 8, 2028
DoxoHealth 50Doxorubicin Hydrochloride
50 mg Lyophilized Powder for IV Injection/InfusionUSP Type I Clear and Colorless Glass Vial with Pink Cover (Box of 1's)
RxVAT-exempt
ADMAC LifesciencesIndia
Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp.
DRP-8425-03
Aug 8, 2028
Doxonish-10Doxorubicin Hydrochloride
10 mg Lyophilized Powder for IV Injection/InfusionUSP Type I Clear and Colorless Glass Vial in white opaque PVC blister tray with transparent cover (Box of 1's)
RxVAT-exempt
ADMAC LifesciencesIndia
Pharmastar Int'l Trading Corp.
DRP-8962
Aug 8, 2028
Doxonish-50Doxorubicin Hydrochloride
50 mg Lyophilized Powder for IV Injection/InfusionUSP Type I Clear and Colorless Glass Vial in white opaque PVC blister tray with transparent cover Box of 1 's
RxVAT-exempt
Admac LifesciencesIndia
Pharmastar Int'l Trading Corp.
DR-XY42394
Aug 8, 2028
Doxonorm-10Doxorubicin hydrochloride
10 mg Lyophilized Powder for Injection for I.V. InfusionUSP Type I colorless glass vial with rubber plug and sealed with magenta color flip-off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Ambica International CorporationTrader: Unicare Healthsciences Pvt. Ltd.
DRP-10989
Dec 29, 2031
Doxonorm-50Doxorubicin hydrochloride
50 mg Lyophilized Powder for Injection for I.V. InfusionUSP Type I colorless glass vial with rubber plug and sealed with magenta color flip-off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Pharma 518, Inc.Importer: Ambica International CorporationTrader: Unicare Healthsciences Pvt. Ltd.
DRP-10967
Jan 17, 2032
DoxorubaDoxorubicin hydrochloride
2 mg/mL Solution for Injection (I.V.)5 mL and 30 mL Type I Amber Glass Vial (Box of 1’s) with Net Content of 5 mL and 25 mL, respectively
RxVAT-exempt
Getwell PharmaceuticalsIndia
Ambica International Corporation
DRP-4794
Oct 7, 2028
DoxoruceenDoxorubicin hydrochloride
50 mg Lyophilized Powder for Injection (IV)30 mL capacity USP Type I clear and colorless glass vial sealed with bromobutyl rubber stopper and red flip-off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Noble Pharma Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-7540-01
Dec 7, 2027
DoxrucinDoxorubicin Hydrochloride
2 mg/mL (20 mg/10 mL) Pegylated Liposomal Concentrated Solution for I.V. InfusionUSP Type I Flint Tubular Glass Vial x 10 mL (Box of 1’s)
RxVAT-exempt
Khandelwal Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: BDR Pharmaceuticals Int’l Pvt. Ltd.
DRP-7095-03
Jan 16, 2037
Doxstar 10Doxorubicin Hydrochloride
10 mg Lyophilized Powder for IV Injection/InfusionUSP Type I Clear and Colorless Glass Vial in white opaque PVC Blister tray with transparent cover (Box of 1's)
RxVAT-exempt
ADMAC LifesciencesIndia
Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp.
DRP-8962-01
Aug 8, 2028
Doxstar 50Doxorubicin Hydrochloride
50 mg Lyophilized Powder for Injection/InfusionUSP Type I Clear and Colorless Glass Vial in White Opaque PVC Blister Tray with Transparent Cover (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp.
DRP-8425-01
Aug 8, 2028
Doxvex 50Doxorubicin Hydrochloride
50 mg Powder for Injection (IV)USP Type I Clear Glass Vial with Pink Flip-Off Seal (Box of 1’s)
RxVAT-exempt
Admac LifesciencesIndia
VE Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd.
DR-XY45366
May 4, 2031
EbedoxoDoxorubicin Hydrochloride
10 mg/5 mL (2 mg/mL) Solution for Injection (I.V./I.A./Intravesicular)Amber Glass Vial with rubber stopper and red flip-off cap x 5mL Box of 1's
RxVAT-exempt
Fareva Unterach GmbHAustria
Sandoz Philippines Corporation
DR-XY25424
Jul 28, 2029
Emidoxoru-50Doxorubicin Hydrochloride
50 mg Lyophilized Powder for IV Injection/InfusionUSP Type I Clear and Colorless Glass Vial with Pink Cover (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Eminent Healthcare Inc.Importer: Pharmastar Int'l Trading Corp.
DRP-8425-04
Aug 8, 2028
EorubicinDoxorubicin Hydrochloride
10 mg Lyophilized Powder for Injection (IV Infusion)Clear Glass vial with Aluminum Flip-Off Seal Cap x 1's (Box of 1's)
RxVAT-exempt
Zee Laboratories LimitedIndia
Importer: Eon Pharmatek Inc.
DR-XY47701
Feb 15, 2027
EorubicinDoxorubicin Hydrochloride
10 mg Lyophilized Powder for Injection (IV Infusion)Clear Glass vial with Aluminum Flip-Off Seal Cap x 1's (Box of 1’s)
RxVAT-exempt
Zee Laboratories LimitedIndia
Importer: Eon Pharmatek Inc.
DRP-15058
Feb 15, 2027
Fin-Dox 50Doxorubicin hydrochloride
2 mg/mL (50 mg/25 mL) Solution for IV Injection25mL in 30mL capacity type I Amber colored glass vial with butyl rubber stopper and aluminum seal with red polypropylene flip-off cap (net content) (Box of 1's)
RxVAT-exempt
Venus Remedies, LimitedIndia
Finstad Inc.
DRP-13790
Apr 20, 2028
Haelan-50Doxorubicin Hydrochloride
50 mg Lyophilized Powder for Injection (IV)Flint Tubular Type I Glass Vial x 25 mL with 20 mm Slotted GBBR Stopper and sealed with White Flip-off Aluminum Seal (Box of 1's)
RxVAT-exempt
Khandelwal Laboratories Pvt. Ltd.India
Kaufmann Pharma Inc.Importer: Medethix, Inc.
DRP-10197-01
Oct 1, 2031
Lipo-DoxDoxorubicin Hydrochloride
2 mg/mL Solution for InjectionUSP Type I Glass Vial x 10 mL (Box of 10's)
RxVAT-exempt
TTY Biopharm Company Limited Chungli FactoryTaiwan
Onco Care Pharma CorporationImporter: American Taiwan Biopharma Phil. Inc,
DR-XY41292
Oct 23, 2027
Lippod 20Doxorubicin Hydrochloride
2 mg/mL (20mg/ 10mL) Solution for Liposomal Injection (IV)10 mL USP Type I Borosilicate Glass Vial with Rubber Stopper (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
I.E, Medica, Inc.
DRP-11180
Feb 9, 2027
Lippod 50Doxorubicin Hydrochloride
2 mg/mL (50 mg/25mL) Solution for Liposomal Injection (IV)30 mL USP Type I Borosilicate Glass Vial with Rubber Stopper (Box of l's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
I.E, Medica, Inc.
DRP-11181
Feb 9, 2027
LypodoxoDoxorubicin Hydrochloride
2 mg/mL (20 mg/10 mL) Pegylated Liposomal Concentrated Solution for I.V. InfusionUSP Type I Flint Tubular Glass Vial in 10 mL (net content) (Box of 1’s)
RxVAT-exempt
Khandelwal Laboratories Pvt. Ltd.India
Genace Pharma DistributorImporter: Ambica International CorporationTrader: BDR Pharmaceuticals Int’l Pvt. Ltd.
DRP-7095-01
Jan 16, 2032
Metodox 10Doxorubicin Hydrochloride
10 mg Lyophilized Powder for Injection (IV)USP Type I Flint Tubular Glass Vial (Box of 1's)
RxVAT-exempt
Neon Laboratories Ltd.India
Ambica International Corporation
DRP-6037
Feb 11, 2029
Metodox 50Doxorubicin Hydrochloride
50 mg Lyophilized Powder for Injection (I.V.)USP Type I Flint Tubular Glass Vial (Box of 1's)
RxVAT-exempt
Neon Laboratories Ltd.India
Ambica International Corporation
DRP-6038
Feb 11, 2029
NatdoxDoxorubicin Hydrochloride
2 mg/mL (20 mg/10 mL) Pegylated Liposomal Concentrated Solution for I.V. InfusionUSP Type I Flint Tubular Glass Vial x 10 mL (Net Content) (Box of 1’s)
RxVAT-exempt
Khandelwal Laboratories Pvt. Ltd.India
Natco Lifesciences Philippines Inc.Importer: Ambica International CorporationTrader: BDR Pharmaceuticals Int’l Pvt. Ltd.
DRP-7095-04
Jan 16, 2027
Natdox-LPDoxorubicin Hydrochloride
2 mg/mL (20 mg/10 mL) Pegylated Liposomal Concentrate Solution for I.V. InfusionUSP Type I Transparent Tubular Glass Vial with 20 mm Grey Bromobutyl Rubber Stopper and 20 mm Aluminum Flip-off Seals with Dark Blue Colour Button x 10 mL (Box of 1's)
RxVAT-exempt
Natco Pharma Limited (Pharma Division)India
Natco Lifesciences Philippines Inc.
DRP-9235
Oct 16, 2030
Natdox-LpDoxorubicin Hydrochloride
2 mg/mL (50 mg/25 mL) Pegylated Liposomal Concentrate Solution for Injection for I.V. InfusionUSP Type I Transparent Tubular Glass Vial with 20 mm Grey Bromobutyl Rubber Stopper and 20 mm Aluminum Flip-off Seals with Dark Red Colour Button x 25 mL (Box of 1's)
RxVAT-exempt
Natco Pharma LimitedIndia
Natco Lifesciences Philippines Inc.
DRP-9234
Oct 16, 2030
NoneDoxorubicin Hydrochloride
10 mg Lyophilized Powder for Injection (IV)USP Type I Glass Vial (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
Medethix, Inc.Importer: I.E. Medica, Inc.
DRP-2299-01
Jul 2, 2028
NoneDoxorubicin hydrochloride
2 mg/mL Solution for Injection (I.V.)30 mL Type I Amber Glass Vial with Net Content of 25 mL (Box of 1’s)
RxVAT-exempt
Getwell PharmaceuticalsIndia
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-4794-04
Oct 7, 2028
NoneDoxorubicin Hydrochloride
50 mg Lyophilized Powder for Injection (I.V.)30 mL-Capacity USP Type I Clear Glass Vial with Bromobutyl Rubber Stopper and Magenta colored Aluminum Flip-Off Seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Genace Pharma DistributorImporter: Suhitas Pharmaceuticals Inc.
DRP-13423-01
Feb 15, 2028
NoneDoxorubicin Hydrochloride
50 mg Lyophilized Powder for Injection (IV)USP Type I Glass Vial with Rubber Stopper and Red Flip-off Seal (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
Medethix, Inc.Importer: I.E. Medica, Inc.
DRP-2300-01
Jul 2, 2028
Nudoxa PEGDoxorubicin hydrochloride
2 mg/mL Pegylated Liposomal Concentrate for Solution for IV InfusionUSP Type I Clear Glass Vial with Rubber Stopper and Violet colored Flip-Off Seal x 10 mL (Box of 1's)
RxVAT-exempt
Zydus Lifesciences LimitedIndia
Zydus Healthcare Philippines Inc.
DRP-13138
Dec 6, 2032
Oncurexin-10Doxorubicin hydrochloride
10 mg Lyophilized Powder for Injection for I.V. InfusionUSP Type I colorless glass vial with rubber plug and sealed with magenta color flip-off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Ambica International CorporationTrader: Unicare Healthsciences Pvt. Ltd.
DRP-10988
Dec 29, 2031
Oncurexin-50Doxorubicin hydrochloride
50 mg Lyophilized Powder for Injection for I.V. InfusionUSP Type I colorless glass vial with rubber plug and sealed with magenta color flip-off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Ambica International CorporationTrader: Unicare Healthsciences Pvt. Ltd.
DRP-10968
Dec 27, 2031
Oxoru-10Doxorubicin Hydrochloride
2 mg/mL (10 mg/5 mL) Solution for Injection (I.V.)USP Type I Amber-Colored Tubular Glass Vial Sealed With 20 mm Grey Bromo Butyl Rubber Plug, Aluminum Seal, And 20 mm Red Flip Off Cap x 5 mL (Box of 1's)
RxVAT-exempt
Venus Remedies Ltd.India
Genace Pharma DistributorImporter: Aglobal Care, Inc.
DRP-9148
Sep 18, 2030
Oxoru-50Doxorubicin Hydrochloride
2 mg/mL (50 mg/25 mL) Solution for Injection (I.V.)USP Type I Amber-Colored Tubular Glass Vial Sealed With 20 mm Grey Bromo Butyl Rubber Plug, Aluminum Seal, And 20 mm Red Flip Off Cap X 25 mL (Box of 1's)
RxVAT-exempt
Venus Remedies LimitedIndia
Genace Pharma DistributorImporter: Aglobal Care, Inc.
DRP-9229
Oct 14, 2030
PaxorubicinDoxorubicin hydrochloride
2 mg/ml Solution for Injection (I.V.)5 mL and 30 mL Type I Amber Glass Vial with Net content of 5 mL and 25 mL, respectively (Box of 1’s)
RxVAT-exempt
Getwell PharmaceuticalsIndia
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation
DRP-4794-03
Oct 7, 2028
PegilyxDoxorubicin hydrochloride
2 mg/mL (20 mg/10 mL) Pegylated Liposomal Suspension for Intravenous InfusionType I borosilicate glass tubular injection vial with butyl rubber stopper x 10 mL (net content). (Box of 1’s)
RxVAT-exempt
CSPC Ouyi Pharmaceutical Co. Ltd.China
AMB HK Enterprises Inc.
DRP-8744
Mar 12, 2031
PegpaxorubicinDoxorubicin Hydrochloride
2 mg/mL (20 mg/10 mL) Pegylated Liposomal Concentrated Solution for I.V. InfusionUSP Type I Flint Tubular Glass Vial x 10 mL (Box of 1’s)
RxVAT-exempt
Khandelwal Laboratories Pvt. Ltd.India
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: BDR Pharmaceuticals Int’l Pvt. Ltd.
DRP-7095-02
Jan 16, 2032
RubicinDoxorubicin HCl
10 mg Lyophilized Powder for Intravenous Injection10 mL USP Type I Clear Glass Vial with Red Flip-off Seal (Box of 1's)
RxVAT-exempt
Beacon Pharmaceuticals LimitedBangladesh
UNILAB, IncImporter: UNILAB, Inc.
DR-XY42578
Sep 6, 2028
RubicinDoxorubicin HCl
50 mg Lyophilized Powder for Intravenous Injection50 mL USP Type I Clear Glass Vial with Red Flip-off Seal (Box of 1's)
RxVAT-exempt
Beacon Pharmaceuticals LimitedBangladesh
UNILAB, Inc.
DR-XY42579
Sep 6, 2028
RubisarDoxorubicin hydrochloride
2 mg/mL Concentrate Solution for I.V. InfusionType I borosilicate colorless glass vial in 5 mL and 25 mL (net content) Box of 1's
RxVAT-exempt
Sichuan Huiyu Pharmaceutical Company LimitedChina
Oncolife Corporation
DR-XY46718
Sep 18, 2029
RuxodoxDoxorubicin hydrochloride
2 mg/ml Solution for Injection (I.V.)5 mL and 30 mL Type I Amber Glass Vial with Net Content of 5 mL and 25 mL Box of 1’s
RxVAT-exempt
Getwell PharmaceuticalsIndia
Ellebasy Medicale TradingImporter: Ambica International Corporation
DRP-4794-01
Oct 7, 2028
Thrabene 10Doxorubicin Hydrochloride
10 mg Lyophilized Powder for Injection (IV)USP Type I Glass Vial (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
Medethix Inc.Importer: I.E Medica Inc.
DRP-2299-02
Jul 2, 2028
Thrabene 50Doxorubicin Hydrochloride
50 mg Lyophilized Powder for Injection (IV)USP Type I Glass Vial with Rubber Stopper and Red Flip-off Seal (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
MedEthix Inc.Importer: I.E Medica Inc.
DRP-2300-02
Jul 2, 2028
XorugenDoxorubicin Hydrochloride
50 mg Lyophilized Powder for Injection (I.V.)30 mL -Capacity USP Type I Clear Glass Vial with Bromobutyl Rubber Stopper and Magenta colored Aluminum Flip-Off Seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Genace Pharma DistributorImporter: Suhitas Pharmaceuticals Inc.
DRP-13423-02
Feb 15, 2028
Xorutic-10Doxorubicin Hydrochloride
10 mg Lyophilized Powder for Injection (IV)10 mL USP Type I Clear Glass Vial (Box of 1 's)
RxVAT-exempt
Adley Formulations Pvt. Ltd.India
ASA Life Philippines Limited Inc
DRP-5772
Nov 19, 2028
Xorutic-50Doxorubicin Hydrochloride
50 mg Lyophilized Powder for Injection (IV)30 mL USP Type I Clear Glass Vial (Box of 1's)
RxVAT-exempt
Adley Formulations Pvt. Ltd.India
ASA Life Philippines Limited Inc
DRP-5773
Nov 19, 2029
Zodox-50Doxorubicin
2 mg/mL (50 mg/25 mL) Concentrate Solution for IV InfusionClear molded glass vial with 20mm chlorobutyl rubber stopper and 20mm aluminum flip off pink seal x 25 mL (Box of 1s)
RxVAT-exempt
INTAS PHARMACEUTICALS LIMITEDIndia
Accord Healthcare Limited - Philippine Branch Office
DRP-8378
Sep 18, 2029
(no brand name)Doxorubicin Hydrochloride
2 mg/mL (20mg/ 10mL) Solution for Liposomal Injection (IV)10 mL USP Type I Borosilicate Glass Vial with Rubber Stopper (Box of l's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
I.E, Medica, Inc.
DRP-11141
Feb 8, 2027
(no brand name)Doxorubicin Hydrochloride
2 mg/mL (50mg/25mL) Solution for Liposomal Injection (IV)30 mL USP Type I Borosilicate Glass Vial with Rubber Stopper (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
I.E, Medica, Inc.
DRP-11140
Feb 8, 2027
(no brand name)Doxorubicin Hydrochloride
2mg/mL (50mg/25mL) Solution for Injection for I.V. InfusionUSP Type I amber coloured glass vial with rubber stopper and aluminum seal and polypropylene flip off cap x 25 mL (Box of 1's)
RxVAT-exempt
Venus Remedies, LimitedIndia
VE Pharma, Inc.Trader: Vexxa Life Sciences Pvt Ltd.
DR-XY48626
Feb 14, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Doxorubicin Hydrochloride Injection: o 10 mg/5 mL, 20 mg/10 mL and 50 mg/25 mL (2 mg/mL) clear red solution in a single-dose vial o 150 mg/75 mL and 200 mg/100 mL (2 mg/mL) clear red solution in a multiple-dose vial Injection: o 10 mg/5 mL, 20 mg/10 mL, 50 mg/25 mL in single-dose vial (3) o 150 mg/75 mL, and 200 mg/100 mL in multiple-dose vial (3)

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label
  • • Radiation-Induced Toxicity: Can be increased by the administration of Doxorubicin Hydrochloride Injection. Radiation recall can occur in patients who receive Doxorubicin Hydrochloride Injection after prior radiation therapy. (5.7)
  • • Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and on the use of effective contraception. Advise males with female partners of reproductive potential to use effective contraception. Advise males with pregnant partners to use condoms. (5.8, 8.1, 8.3)
5.1 Cardiomyopathy and Arrhythmias

5.1 Cardiomyopathy and Arrhythmias Cardiomyopathy Doxorubicin hydrochloride can result in myocardial damage, including acute left ventricular failure. The risk of cardiomyopathy is generally proportional to the cumulative exposure. Include prior doses of other anthracyclines or anthracenediones in calculations of total cumulative dosage for doxorubicin hydrochloride.

Cardiomyopathy may develop during treatment or up to several years after completion of treatment and can include decrease in LVEF and signs and symptoms of congestive heart failure (CHF). The probability of developing cardiomyopathy is estimated to be 1 to 2% at a total cumulative dose of 300 mg/m 2 of doxorubicin hydrochloride, 3 to 5% at a dose of 400 mg/m 2, 5 to 8% at a dose of 450 mg/m 2, and 6 to 20% at a dose of 500 mg/m 2, when doxorubicin hydrochloride is administered every 3 weeks.

There is an additive or potentially synergistic increase in the risk of cardiomyopathy in patients who have received radiotherapy to the mediastinum or concomitant therapy with other known cardiotoxic agents, such as cyclophosphamide and trastuzumab. Pericarditis and myocarditis have also been reported during or following doxorubicin hydrochloride treatment.

Assess left ventricular cardiac function (e.g., MUGA or echocardiogram) prior to initiation of Doxorubicin Hydrochloride Injection, during treatment to detect acute changes, and after treatment to detect delayed cardiotoxicity. Increase the frequency of assessments as the cumulative dose exceeds 300 mg/m 2. Use the same method of assessment of LVEF at all time points [see Use in Specific Populations (8.4)].

Discontinue Doxorubicin Hydrochloride Injection in patients who develop signs or symptoms of cardiomyopathy [see Dosage and Administration (2.3)]. Consider the use of dexrazoxane to reduce the incidence and severity of cardiomyopathy due to doxorubicin hydrochloride administration in patients who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m 2 and who will continue to receive doxorubicin hydrochloride.

Arrhythmias Doxorubicin hydrochloride can result in arrhythmias, including life-threatening arrhythmias, during or within a few hours after doxorubicin hydrochloride administration and at any time point during treatment. Tachyarrhythmias, including sinus tachycardia, premature ventricular contractions, and ventricular tachycardia, as well as bradycardia, can occur.

Electrocardiographic changes, including non-specific ST-T wave changes, atrioventricular and bundle-branch block can also occur. These electrocardiographic changes may be transient and self-limited and may not require a dosage modification of doxorubicin hydrochloride.

5.2 Secondary Malignancies

5.2 Secondary Malignancies The risk of developing secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) is increased following treatment with doxorubicin hydrochloride. Cumulative incidences ranged from 0.2% at five years to 1.5% at 10 years in two separate trials involving the adjuvant treatment of women with breast cancer.

These leukemias generally occur within 1 to 3 years of treatment.

5.3 Extravasation and Tissue Necrosis

5.3 Extravasation and Tissue Necrosis Extravasation of doxorubicin hydrochloride can cause severe local tissue injury manifesting as blistering, ulceration, and necrosis requiring wide excision of the affected area and skin grafting. Extravasation should be considered if a patient experiences a burning or stinging sensation or shows other evidence indicating peri-venous infiltration or extravasation; however, extravasation may be present in patients who do not experience a stinging or burning sensation or when blood return is present on aspiration of the infusion needle.

When given via a peripheral venous line, infuse Doxorubicin Hydrochloride Injection over 10 minutes or less to minimize the risk of thrombosis or perivenous extravasation. If extravasation is suspected, immediately discontinue the intravenous injection or continuous intravenous infusion [see Dosage and Administration (2.5)].

Apply ice to the site intermittently for 15 minutes, 4 times a day for 3 days. In adults, if appropriate, administer dexrazoxane at the site of extravasation as soon as possible and within the first 6 hours after extravasation.

5.4 Severe Myelosuppression

5.4 Severe Myelosuppression Doxorubicin hydrochloride can cause myelosuppression. In Study 1, the incidence of severe myelosuppression was: grade 4 leukopenia (0.3%), grade 3 leukopenia (3%), and grade 4 thrombocytopenia (0.1%). A dose-dependent, reversible neutropenia is the predominant manifestation of myelosuppression from doxorubicin hydrochloride.

When doxorubicin hydrochloride is administered every 21 days, the neutrophil count reaches its nadir 10 to 14 days after administration with recovery usually occurring by day 21. Obtain complete blood counts prior to each treatment and carefully monitor patients during treatment for possible clinical complications due to myelosuppression.

Delay next dose of Doxorubicin Hydrochloride Injection if severe myelosuppression has not improved. Consider dose reduction for patients with prolonged myelosuppression based on severity of reaction.

5.5 Use in Patients with Hepatic Impairment

5.5 Use in Patients with Hepatic Impairment The clearance of doxorubicin is decreased in patients with elevated serum bilirubin with an increased risk of toxicity [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)]. Doxorubicin Hydrochloride Injection is contraindicated in patients with severe hepatic impairment (defined as Child Pugh Class C or serum bilirubin level greater than 5 mg/dL) [see Contraindications (4)].

Reduce the dose of Doxorubicin Hydrochloride Injection in patients with serum bilirubin levels of 1.2 to 5 mg/dL [see Dosage and Administration (2.4)]. Obtain liver tests including ALT, AST, alkaline phosphatase, and bilirubin prior to and during therapy.

5.6 Tumor Lysis Syndrome

5.6 Tumor Lysis Syndrome Doxorubicin hydrochloride can induce tumor lysis syndrome in patients with rapidly growing tumors. Evaluate blood uric acid levels, potassium, calcium, phosphate, and creatinine after initial treatment. Hydration, urine alkalinization, and prophylaxis with allopurinol to prevent hyperuricemia may minimize potential complications of tumor lysis syndrome.

5.7 Potentiation of Radiation Toxicity

5.7 Potentiation of Radiation Toxicity and Radiation Recall Doxorubicin hydrochloride can increase radiation-induced toxicity to the myocardium, mucosa, skin, and liver. Radiation recall, including but not limited to cutaneous and pulmonary toxicity, can occur in patients who receive doxorubicin hydrochloride after prior radiation therapy.

5.8 Embryo-Fetal Toxicity

5.8 Embryo-Fetal Toxicity Based on findings in animals and its mechanism of action, Doxorubicin Hydrochloride Injection can cause fetal harm when administered to a pregnant woman; avoid the use of Doxorubicin Hydrochloride Injection during the 1 st trimester. Available human data do not establish the presence or absence of major birth defects and miscarriage related to the use of doxorubicin hydrochloride during the 2 nd and 3 rd trimesters.

Doxorubicin hydrochloride was teratogenic and embryotoxic in rats and rabbits at doses lower than the recommended human dose. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with Doxorubicin Hydrochloride Injection and for 6 months after treatment.

Advise males with female partners of reproductive potential to use effective contraception during treatment with Doxorubicin Hydrochloride Injection and for 3 months after treatment. Advise males with pregnant partners to use condoms during treatment with Doxorubicin Hydrochloride Injection and for at least 10 days after the final dose [see Use in Specific Populations (8.1, 8.3), Nonclinical Toxicology (13.1)].

Drug interactions

Drug interactions (US label) US FDA label
  • • Avoid concomitant use of doxorubicin hydrochloride with inhibitors and inducers of CYP3A4, CYP2D6, and/or P-gp (7.1)
  • • Do not administer doxorubicin hydrochloride in combination with trastuzumab due to increased risk of cardiac dysfunction (5.1, 7.2)
7.1 Effect of Other Drugs on Doxorubicin Hydrochloride Injection Inhibitors of CYP3A4,…

7.1 Effect of Other Drugs on Doxorubicin Hydrochloride Injection Inhibitors of CYP3A4, CYP2D6, and P-gp Concomitant use of doxorubicin hydrochloride with inhibitors of CYP3A4, CYP2D6, or P-glycoprotein (P-gp), increased concentrations of doxorubicin, which may increase the incidence and severity of adverse reactions of doxorubicin hydrochloride. Avoid concomitant use of Doxorubicin Hydrochloride Injection with inhibitors of CYP3A4, CYP2D6, or P-gp.

Inducers of CYP3A4, CYP2D6, or P-gp Concomitant use of doxorubicin hydrochloride with inducers of CYP3A4, CYP2D6, or P-gp may decrease the concentration of doxorubicin. Avoid concomitant use of Doxorubicin Hydrochloride Injection with inducers of CYP3A4, CYP2D6, or P-gp. Paclitaxel Paclitaxel, when given prior to doxorubicin hydrochloride, increases the plasma-concentrations of doxorubicin and its metabolites.

Administer Doxorubicin Hydrochloride Injection prior to paclitaxel if used concomitantly.

7.2 Concomitant Use of Trastuzumab

7.2 Concomitant Use of Trastuzumab Concomitant use of trastuzumab and doxorubicin hydrochloride results in an increased risk of cardiac dysfunction. Avoid concomitant administration of Doxorubicin Hydrochloride Injection and trastuzumab [see Warnings and Precautions (5.1)]. Patients receiving doxorubicin after stopping treatment with trastuzumab may also be at an increased risk of developing cardiotoxicity.

Trastuzumab may persist in the circulation for up to 7 months. Therefore, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab when possible. If anthracyclines are used before this time, carefully monitor cardiac function.

7.3 Concomitant Use of Dexrazoxane

7.3 Concomitant Use of Dexrazoxane Do not administer dexrazoxane as a cardioprotectant at the initiation of doxorubicin hydrochloride-containing chemotherapy regimens. In a randomized trial in women with metastatic breast cancer, initiation of dexrazoxane with doxorubicin hydrochloride-based chemotherapy resulted in a significantly lower tumor response rate (48% vs. 63%; p = 0.007) and shorter time to progression compared to doxorubicin hydrochloride-based chemotherapy alone.

7.4 Concomitant Use of 6

7.4 Concomitant Use of 6-Mercaptopurine Doxorubicin hydrochloride may potentiate 6-mercaptopurine-induced hepatotoxicity. In 11 patients with refractory leukemia treated with 6-mercaptopurine (500 mg/m 2 intravenously daily for 5 days per cycle every 2–3 weeks) and doxorubicin hydrochloride (50 mg/m 2 intravenous once per cycle every 2–3 weeks) alone or with vincristine and prednisone, all developed hepatic dysfunction manifested by increased total serum bilirubin, alkaline phosphatase and aspartate aminotransferase.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Metabolism Doxorubicin is a substrate of CYP3A4, CYP2D6, and P-gp.

Avoid concomitant use of Doxorubicin Hydrochloride Injection with inhibitors of CYP3A4, CYP2D6, or P-gp.

Inducers of CYP3A4, CYP2D6, or P-gp Concomitant use of doxorubicin hydrochloride with inducers of CYP3A4, CYP2D6, or P-gp may decrease the concentration of doxorubicin.

Avoid concomitant use of Doxorubicin Hydrochloride Injection with inducers of CYP3A4, CYP2D6, or P-gp.

Adverse reactions

Adverse reactions (US label) US FDA label
  • The following clinically significant adverse reactions are described elsewhere in the labeling. • Cardiomyopathy and Arrhythmias [see Warnings and Precautions (5.1)] • Secondary Malignancies [see Warnings and Precautions (5.2)] • Extravasation and Tissue Necrosis [see Warnings and Precautions (5.3)] • Severe Myelosuppression [see Warnings and Precautions (5.4)] • Tumor Lysis Syndrome [see Warnings and Precautions (5.6)] • Radiation Sensitization and Radiation Recall [see Warnings and Precautions (5.7)] The most common (>10%) adverse reactions are alopecia, nausea and vomiting. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Breast Cancer The safety data below were collected from 1492 women who received doxorubicin hydrochloride at a dose of 60 mg/m 2 and cyclophosphamide at a dose of 600 mg/m 2 (AC) every 3 weeks for 4 cycles for the adjuvant treatment of axillary lymph node positive breast cancer.

The median number of cycles received was 4. Selected adverse reactions reported in this study are provided in Table 2. No treatment-related deaths were reported in patients on either arm of the study. Table 2. Selected Adverse Reactions in Patients with Early Breast Cancer Involving Axillary Lymph Nodes Adverse Reactions AC Includes pooled data from patients who received either AC for 4 cycles or AC for 4 cycles followed by CMF for 3 cycles N = 1492 Conventional CMF N = 739 % % AC = doxorubicin hydrochloride, cyclophosphamide; CMF = cyclophosphamide, methotrexate, fluorouracil Alopecia 92 71 Vomiting Vomiting ≤12 hours 34 25 Vomiting >12 hours 37 12 Intractable 5 2 Leukopenia Grade 3 (1,000–1,999 /mm 3) 3.4 9.4 Grade 4 (<1000 /mm 3) 0.3 0.3 Shock, sepsis 2 1 Systemic infection 2 1 Cardiac dysfunction Asymptomatic 0.2 0.1 Transient 0.1 0 Symptomatic 0.1 0 Thrombocytopenia Grade 3 (25,000–49,999 /mm 3) 0 0.3 Grade 4 (<25,000 /mm 3) 0.1 0

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of Doxorubicin Hydrochloride Injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Cardiac – Cardiogenic shock Cutaneous – Skin and nail hyperpigmentation, oncolysis, rash, itching, photosensitivity, urticaria, acral erythema, palmar plantar erythrodysesthesia Gastrointestinal – Nausea, mucositis, stomatitis, necrotizing colitis, typhlitis, gastric erosions, gastrointestinal tract bleeding, hematochezia, esophagitis, anorexia, abdominal pain, dehydration, diarrhea, hyperpigmentation of the oral mucosa Hypersensitivity – Anaphylaxis Laboratory Abnormalities – Increased ALT, increased AST Neurological – Peripheral sensory and motor neuropathy, seizures, coma Ocular – Conjunctivitis, keratitis, lacrimation Vascular – Phlebosclerosis, phlebitis/thrombophlebitis, hot flashes, thromboembolism Other – Malaise/asthenia, fever, chills, weight gain

Adverse reaction frequency tables (US label) US FDA label
Table 2. Selected Adverse Reactions in Patients with Early Breast Cancer Involving Axillary Lymph Nodes
Adverse ReactionsACIncludes pooled data from patients who received either AC for 4 cycles or AC for 4 cycles followed by CMF for 3 cycles N = 1492Conventional CMF N = 739
%%
AC = doxorubicin hydrochloride, cyclophosphamide; CMF = cyclophosphamide, methotrexate, fluorouracil
Alopecia9271
Vomiting
Vomiting ≤12 hours3425
Vomiting >12 hours3712
Intractable52
Leukopenia
Grade 3 (1,000–1,999 /mm3)3.49.4
Grade 4 (<1000 /mm3)0.30.3
Shock, sepsis21
Systemic infection21
Cardiac dysfunction
Asymptomatic0.20.1
Transient0.10
Symptomatic0.10
Thrombocytopenia
Grade 3 (25,000–49,999 /mm3)00.3
Grade 4 (<25,000 /mm3)0.10

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Based on findings in animals and its mechanism of action, Doxorubicin Hydrochloride Injection can cause fetal harm when administered to a pregnant woman; avoid the use of Doxorubicin Hydrochloride Injection during the 1 st trimester. Available human data do not establish the presence or absence of major birth defects and miscarriage related to the use of doxorubicin hydrochloride during the 2 nd and 3 rd trimesters.

Doxorubicin hydrochloride was teratogenic and embryotoxic in rats and embryotoxic in rabbits when administered during organogenesis at doses approximately 0.07 times (based on body surface area) the recommended human dose of 60 mg/m 2 (see Data). Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Data Animal Data Doxorubicin hydrochloride was teratogenic and embryotoxic at doses of 0.8 mg/kg/day (about 0.07 times the recommended human dose based on body surface area) when administered during the period of organogenesis in rats. Teratogenicity and embryotoxicity were also seen using discrete periods of treatment.

The most susceptible was the 6- to 9-day gestation period at doses of 1.25 mg/kg/day and greater. Characteristic malformations included esophageal and intestinal atresia, tracheo-esophageal fistula, hypoplasia of the urinary bladder, and cardiovascular anomalies. Doxorubicin hydrochloride was embryotoxic (increase in embryo‑fetal deaths) and abortifacient at 0.4 mg/kg/day (about 0.07 times the recommended human dose based on body surface area) in rabbits when administered during the period of organogenesis.

Mechanism of action

12.1 Mechanism of Action The cytotoxic effect of doxorubicin hydrochloride on malignant cells and its toxic effects on various organs are thought to be related to nucleotide base intercalation and cell membrane lipid binding activities of doxorubicin. Intercalation inhibits nucleotide replication and action of DNA and RNA polymerases. The interaction of doxorubicin with topoisomerase II to form DNA-cleavable complexes appears to be an important mechanism of doxorubicin hydrochloride cytocidal activity.

US FDA label

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Distribution The distribution half-life is approximately 5 minutes.

The terminal half-life is 20 hours to 48 hours.

Disposition of doxorubicinol in patients is formation rate limited, with the terminal half-life of doxorubicinol being similar to doxorubicin.

Excretion Plasma clearance is predominately by metabolism and biliary excretion.

However, the terminal half-life of doxorubicin was longer in men compared to women (54 versus 35 hours).

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Pharmacokinetic studies conducted in patients with various types of tumors have shown that doxorubicin follows multiphasic disposition after intravenous injection. In four patients, doxorubicin demonstrated dose-independent pharmacokinetics across a dose range of 30 mg/m 2 to 70 mg/m 2. Distribution The distribution half-life is approximately 5 minutes.

Steady-state distribution volume ranges from 809 L/m 2 to 1214 L/m 2. Binding of doxorubicin and its major metabolite, doxorubicinol, to plasma proteins is 75% and is independent of plasma concentration of doxorubicin up to 1.1 µg/mL. Doxorubicin does not cross the blood brain barrier. Elimination Plasma clearance is ranges from 324 mL/min/m 2 to 809 mL/min/m 2.

The terminal half-life is 20 hours to 48 hours. Metabolism Doxorubicin is a substrate of CYP3A4, CYP2D6, and P-gp. Enzymatic reduction at the 7 position and cleavage of the daunosamine sugar yields aglycones which are accompanied by free radical formation, the local production of which may contribute to the cardiotoxic activity of doxorubicin hydrochloride.

Disposition of doxorubicinol in patients is formation rate limited, with the terminal half-life of doxorubicinol being similar to doxorubicin. The relative exposure of doxorubicinol, i.e., the ratio between the AUC of doxorubicinol and the AUC of doxorubicin is approximately 0.5. Excretion Plasma clearance is predominately by metabolism and biliary excretion.

Approximately 40% of the dose appears in the bile in 5 days, while only 5% to 12% of the drug and its metabolites appear in the urine during the same time period. In urine, <3% of the dose was recovered as doxorubicinol over 7 days. Specific Populations Weight Systemic clearance of doxorubicin is significantly reduced in obese women with ideal body weight greater than 130%.

There was a significant reduction in clearance without any change in volume of distribution in obese patients when compared with normal patients with less than 115% ideal body weight. Pediatric Patients Following administration of doses ranging from 10 mg/m 2 to 75 mg/m 2 of doxorubicin hydrochloride to 60 patients ranging from 2 months to 20 years, doxorubicin clearance averaged 1443 ± 114 mL/min/m 2.

Further analysis demonstrated that clearance in 52 patients ranging from 2 to 20 years (1540 mL/min/m 2) was increased compared with adults. However, clearance in infants younger than 2 years of age (813 mL/min/m 2) was decreased compared with older patients (ranging from 2 to 20 years) and approached the range of clearance values determined in adults [see Use in Specific Populations (8.4)].

Sex A published clinical study involving 6 men and 21 women with no prior anthracycline therapy reported a significantly higher median doxorubicin clearance in men compared to women (1088 mL/min/m 2 versus 433 mL/min/m 2). However, the terminal half-life of doxorubicin was longer in men compared to women (54 versus 35 hours).

Patients with Hepatic Impairment The clearance of doxorubicin and doxorubicinol was reduced in patients with elevated serum total bilirubin concentrations [see Dosage and Administration (2.4), Warnings and Precautions (5.5)].

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Doxorubicin 2 mg/mL, 25 mL Vial₱396.00–₱725.00Reference ₱484.00per vialDPRI procurement range
Doxorubicin 2 mg/mL, 5 mL Vial₱151.00–₱166.00Reference ₱151.00per vialDPRI procurement range
Doxorubicin 10 mg powder Vial₱160.00–₱425.00Reference ₱160.00per vialDPRI procurement range
Doxorubicin 50 mg powder Vial₱440.20–₱678.00Reference ₱440.20per vialDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Doxorubicin (as hydrochloride)
PNF listingInj.: powder, 10 mg and 50 mg vial (IV)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PNF listingInj.: 2 mg/mL, 5 mL and 25 mL vial (IV)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Doxorubicin Hydrochloride · Pfizer Laboratories Div Pfizer Inc [US FDA-approved label, version 28, May 5, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fd148fb-0fbc-4b6f-b790-23546fb46a71
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .